Announcements Trials
Browse Landscape

Phase

Phase 1 16Phase 2 10Phase 1/2 3Phase EARLY_PHASE1 1

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 2Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 2Carcinoma, Merkel Cell 1

Interventions

pembrolizumab 86Cyclophosphamide 58Carboplatin 57Specimen Handling 55fludarabine 46Nivolumab 44Magnetic Resonance Spectroscopy 44Gemcitabine 41Biopsy 40Bevacizumab 36Dexamethasone 32venetoclax 31Paclitaxel 29Cisplatin 29Pemetrexed 28Injections 28Docetaxel 26atezolizumab 22Ipilimumab 22Capecitabine 22Temozolomide 21Rituximab 20Oxaliplatin 20Cetuximab 20Azacitidine 20Lenalidomide 19Fulvestrant 19abemaciclib 18Fluorouracil 17Vincristine 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × decitabine and cedazuridine drug combination × 90 days × Clear all
NCT07472322 2026-05-29

ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1

University of Wisconsin, Madison

Phase 1/2 Not yet recruiting
31 enrolled
Dermatologic

Carcinoma, Merkel Cell

NCT04774393 2026-05-20

Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
84 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05360160 2026-05-20

A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
43 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡